Critical Role for 24-Hydroxylation in Homeostatic Regulation of Vitamin D Metabolism

Zhinous Shahidzadeh Yazdi, Elizabeth A. Streeten, Hilary B. Whitlatch,

May E. Montasser, Amber L. Beitelshees, and Simeon I. Taylor

Department of Medicine

Division of Endocrinology, Diabetes, and Nutrition

University of Maryland School of Medicine

Baltimore, MD, USA

Corresponding author: Simeon I. Taylor, MD, PhD, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA

Telephone number: +1 301 980 5272

Email: staylor2@som.umaryland.edu

Conflict-of-interest statement: SIT serves as a consultant for Ionis Pharmaceuticals and receives an inventor's share of royalties from NIDDK for metreleptin as a treatment for generalized lipodystrophy. EAS, MEM, and HBW receive research support (unrelated to this project) from the Regeneron Genetics Center. ZSY and ALB have no conflicts to disclose.

Trial registration: NCT02891954 (clinicaltrials.gov)

Funding: National Institute of Diabetes, Digestive, and Kidney Diseases: R01DK118942, R01DK118924-02S1, and T32DK098107

Key words: vitamin D deficiency, 1,25-dihydroxyvitamin D, 24,25-dihydroxyvitamin D, 25-hydroxyvitamin D, parathyroid hormone, homeostatic regulation

ORCID ID# (Simeon I. Taylor): 0000-0001-7500-7854

ABSTRACT

Context. The body has evolved homeostatic mechanisms to maintain free levels of Ca^{+2} and 1,25-dihydroxyvitamin D [1,25$(OH)_2$D] within narrow physiological ranges. Clinical guidelines emphasize important contributions of PTH in maintaining this homeostasis.

Objective. To investigate mechanisms of homeostatic regulation of vitamin D (VitD) metabolism and to apply mechanistic insights to improve clinical assessment of VitD status.

Design. Crossover clinical trial studying participants before and after VitD3-supplementation.

Setting. Community.

Participants. 11 otherwise healthy individuals with VitD-deficiency (25-hydroxyvitamin D [25(OH)D] ≤20 ng/mL).

Interventions. VitD3-supplements (50,000 IU once or twice a week depending on BMI, for 4-6 weeks) were administered to achieve 25(OH)D≥30 ng/mL.

Results. VitD3-supplementation significantly increased mean 25(OH)D by 2.7-fold and 24,25-dihydroxyvitamin D [24,25$(OH)_2$D] by 4.3-fold. In contrast, mean levels of PTH, FGF23, and 1,25$(OH)_2$D did not change in response to VitD3-supplementation. Mathematical modeling suggested that 24-hydroxylase activity was maximal for 25(OH)D≥50 ng/mL and achieved a minimum (~90% suppression) with 25(OH)D<10-20 ng/mL. Suppression of 24-hydroxylase activity was triggered by mild-moderate VitD-deficiency, which sustains physiological levels of 1,25$(OH)_2$D by suppressing metabolic clearance of 1,25$(OH)_2$D. VitD metabolite ratios [e.g., 1,25$(OH)_2$D/24,25$(OH)_2$D] provide useful indices of VitD status. When VitD availability is limited, this suppresses 24-hydroxylase activity – thereby decreasing the level of 24,25$(OH)_2$D

and increasing the $1,25(OH)_2D/24,25(OH)_2D$ ratio. Thus, a high $1,25(OH)_2D/24,25(OH)_2D$ ratio signifies triggering of homeostatic regulation in response to mild-moderate VitD-deficiency.

Conclusions. Suppression of 24-hydroxylase activity provides a first line of defense against symptomatic VitD-deficiency by decreasing metabolic clearance of $1,25(OH)_2D$. The $1,25(OH)_2D/24,25(OH)_2D$ ratio can provide a useful index of clinical VitD status.

INTRODUCTION:

Vitamin D (VitD) plays an essential role in mediating absorption of dietary calcium in the intestine (1-4). Furthermore, as evidenced by diseases such as nutritional rickets, VitD is critical to maintaining bone health (5, 6). The body obtains VitD from two sources. Endogenous production of VitD requires exposure to ultraviolet light, which is variable depending on geographic location and the season of the year among other factors. Dietary intake of VitD is also variable and depends on the VitD content of the diet (including intake of fortified dairy products and dietary supplements) (7, 8). To maintain a consistent *milieu intérieure* (9, 10), each individual must maintain levels of free 1,25-dihydroxyvitamin D [1,25$(OH)_2$D] – the biologically active metabolite of VitD – within a narrow physiological range notwithstanding considerable variation in availability of the biosynthetic precursor (i.e., VitD) (11-13).

We developed a mathematical model to investigate physiological mechanisms mediating homeostatic regulation of VitD metabolism. 24-hydroxylation provides the major mechanism whereby 1,25$(OH)_2$D is cleared (12, 14, 15). According to our mathematical model, *in vivo* activity of 24-hydroxylase varies over an approximately tenfold range. 24-Hydroxylase activity achieves a maximum when 25(OH)D levels exceed 50 ng/mL. By inducing 24-hydroxylase activity when VitD is abundant, the body increases clearance of 1,25$(OH)_2$D – thereby protecting against VitD toxicity. Furthermore, the model suggests that 24-hydroxylase activity achieves a minimum when 25(OH)D is less than 10-20 ng/mL. The resultant decrease in 1,25$(OH)_2$D clearance tends to sustain 1,25$(OH)_2$D levels, thereby compensating for limited availability of VitD and protecting against symptomatic VitD deficiency.

Several feedback loops contribute to homeostatic regulation of VitD – including feedback loops between VitD status and the rates of both production and clearance of 1,25$(OH)_2$D (12, 16-19).

Cannon proposed the concept of the "wisdom of the body" (9), which includes homeostatic mechanisms that are responsible for maintaining a constant *milieu intérieure.* Endocrinologists often leverage the "wisdom of the body" to diagnose states of hormonal excess or hormonal insufficiency based on the level of activation or suppression of homeostatic mechanisms. This is exemplified by the approach to diagnosing patients' hormonal status with respect to hormones that act upon other nuclear hormone receptors (e.g., thyroid hormones or glucocorticoids) by measuring the levels of trophic hormones (e.g., TSH or ACTH) (20, 21). By analogy, we discuss our data in the context of the published literature advocating for a similar approach to assessing VitD status – i.e., by assessing the level of suppression/induction of 24-hydroxylase activity (22-24). By leveraging the wisdom of the body in this assessment, physicians can advance the state-of-the-art of assessment of VitD status.

METHODS

This study ("VitD Sub-study") was part of our ongoing "Genetics of Response to Canagliflozin (GRC)" clinical trial (Clinicaltrials.gov Identifier: NCT02891954) in healthy volunteers recruited from the Old Order Amish population in Lancaster PA, who are non-Hispanic white people. Although participants were excluded from the parent study if their 25(OH)D level ≤20 ng/mL, these VitD deficient individuals were eligible to participate in the VitD Sub-study, which investigated the effects of VitD3 supplements on canagliflozin-triggered changes in the serum phosphorus/FGF23/1,25$(OH)_2$D/PTH axis (13). Participants were required to meet all other inclusion/exclusion criteria for the parent study. The effect of VitD3 supplementation on canagliflozin-induced changes in mineral metabolism biomarkers was reported elsewhere (13). The current paper reports results of a secondary data analysis focusing primarily on the effect VitD3 supplementation on VitD metabolites in participants with mild-moderate VitD deficiency.

Screening and recruitment:

As reported previously, we screened 24 healthy volunteers from September 2019 to July 2021 and enrolled 19 individuals with 25(OH)D levels ≤20 ng/mL who were otherwise eligible to participate in the parent GRC study (13). The Endocrine Society's clinical practice guidelines proposed thresholds of 25(OH)D ≤20 ng/mL (≤50 nmol/L) for VitD deficiency, 21-29 ng/mL (51-74 nmol/L) for VitD insufficiency, and ≥ 30 ng/mL (≥75 nmol/L) for VitD sufficiency (17). We applied The Endocrine Society's definition of VitD deficiency (≤20 ng/mL) as a key inclusion criterion for this sub-study and applied the definition of VitD sufficiency (≥30 ng/mL) as the criterion for adequacy of VitD3 supplementation. Details of demographics, baseline characteristics, recruitment, and disposition are reported elsewhere (13). Because of interruptions and delays associated with the COVID-19 pandemic, we did not complete our plan to study 25

111 research participants. We analyzed data after eleven participants (four females and seven males)
112 completed the entire study protocol.

113 *Endpoints and biomarkers:*

114 We measured levels of the following biomarkers both at baseline and after VitD3
115 supplementation: plasma PTH, plasma FGF23, serum phosphorus, serum calcium, and three
116 VitD metabolites – 25(OH)D, 1,25$(OH)_2$D, and 24,25-dihydroxyvitamin D [24,25$(OH)_2$D].

117 *VitD3 supplementation protocol*

118 VitD deficient participants completed canagliflozin challenge #1 and then received VitD3
119 capsules (Bio-Tech Pharmacal; Fayetteville, AR) in doses of either 50,000 IU per week for
120 participants with BMI <30 kg/m^2 or 50,000 IU twice a week for participants with BMI ≥30 kg/m
121 for four weeks, followed by a second total serum 25(OH)D measurement a week after
122 completion of the four-week VitD3 supplementation protocol (13). If screening serum 25(OH)D
123 levels (Quest Diagnostics) were <30 ng/mL, high-dose VitD3 supplementation was continued.
124 Once screening 25(OH)D (Quest Diagnostics) levels were confirmed to be ≥30 ng/mL,
125 maintenance-dose VitD3 supplementation (1000 IU/d or 2000 IU/d for BMI <30 kg/m^2 or BMI
126 ≥30 kg/m^2, respectively) was continued until completion of canagliflozin challenge #2.

127 *Clinical chemistry*

128 Blood samples obtained at home visits were collected in test tubes as appropriate for each assay
129 (13). Quest Diagnostics conducted an immunoassay for baseline levels of plasma PTH as well as
130 LC-MS/MS assays to measure baseline serum 1,25$(OH)_2$D, and serum 25(OH)D levels. Plasma
131 levels of 25(OH)D and 24,25$(OH)_2$D were assessed using LC-MS/MS assays conducted by
132 Heartland Assays (Ames, IA). Quest's serum 25(OH)D levels were used to determine eligibility

133 for the VitD Sub-study. Heartland's plasma 25(OH)D levels were used to assess the response to
134 VitD3 supplements. We have reported 25(OH)D and 24,25$(OH)_2$D in ng/mL and 1,25$(OH)_2$D in
135 pg/mL. Multiplication by a factor of 2.49 can be used to convert from ng/mL to nmol/L. Mean
136 levels for 25(OH)D before and after VitD3 supplementation, were identical in assays conducted
137 by Quest Diagnostics and Heartland Assays (13). LC-MS/MS assays conducted at both Quest
138 Diagnostics and Heartland Assays distinguished between derivatives of VitD2 and VitD3.
139 Derivatives of VitD2 were not detected in any of our participants' samples. For simplicity, we
140 refer to our data on levels of 25(OH)D, 1,25$(OH)_2$D, or 24,25$(OH)_2$D without specifying D2 or
141 D3. Nevertheless, since D2 derivatives were not detected in any of our participants, this should
142 be understood as referring exclusively to D3 derivatives.

143 *Quality control for VitD assays of VitD metabolites*

144 Heartland Assays provided the following information regarding their assays of VitD metabolites:

145 *25(OH)D and 24,25$(OH)_2$D*. Accuracy >90% based on comparisons to National Institute of
146 Standards and Technology standards. Coefficients of variation for both inter- and intra-assay
147 were < 5%.

148 *Analysis of our data*. We obtained blood samples on three separate days during canagliflozin
149 (300 mg/day) challenge tests: baseline prior to receiving canagliflozin, at 48 hours (after
150 receiving canagliflozin for two days), and at 120 hours (after receiving canagliflozin for five
151 days). Because mean levels of 25(OH)D and 24,25$(OH)_2$D were not affected by canagliflozin,
152 we calculated coefficients of variation based on an assumption that the three separate blood
153 samples obtained from each individual during the canagliflozin challenge test had similar
154 concentrations of those two VitD metabolites. Based on this assumption, we calculated

155 coefficients of variation of 5.8% for 25(OH)D and 11.1% for 24,25$(OH)_2$D. Because these
156 calculated coefficients of variation included day-to-day variation in VitD metabolite levels as
157 well as intra-assay variation, our estimates of coefficients of variation are likely greater than the
158 actual intra-assay variation.

159 Furthermore, we compared mean data for 25(OH)D levels measured in the same individuals in
160 the two assays. Mean 25(OH)D levels before receiving VitD3 supplements were 16.4 and 16.5
161 ng/mL in the Quest and Heartland assays, respectively (13). Mean total 25(OH)D levels after
162 receiving VitD3 supplements were 45.3 and 44.3 ng/mL in the Quest and Heartland assays,
163 respectively (13). In addition, the individual data from the Quest assay (blood obtained on the
164 day of screening) was highly correlated with individual data from the Heartland assay (blood
165 obtained on Day 1 of the canagliflozin challenge test) – with variance in one assay accounting
166 for 81% of the variance in the other assay. Based on these data, we conclude that the two assays
167 provide comparable measurements of 25(OH)D levels. In any case, the Quest assay for 25(OH)D
168 was used only to determine eligibility for the study. The Heartland assay was the sole source of
169 data on 25(OH)D levels used for determination of goodness-of-fit for our model.

170 *Published analysis of Quest's assay of 1,25$(OH)_2$D*. Biancuzzo et al. (25) reported intra- and
171 inter-assay coefficients of variation of 9% and 12%, respectively, for Quest's assay of
172 1,25$(OH)_2$D. In addition, we estimated the inter-assay coefficient of variation based on our
173 observation that 1,25$(OH)_2$D levels were not changed by administration of VitD3 supplements.
174 When we calculated a coefficient of variation for 1,25$(OH)_2$D levels before and after VitD3
175 supplementation, we estimated a coefficient of variation of 13% – very similar to the inter-assay
176 coefficient of variation reported by Biancuzzo et al. (25). Our calculation of coefficient of
177 variation includes at least three components: the coefficient of variation for measurement error,

178 day-to-day variation, and a possible small effect of VitD3 supplementation on 1,25(OH)$_2$D
179 levels. Thus, our estimate of the coefficient of variation represents an upper bound for the actual
180 inter-assay coefficient of variation.

181 *Mathematical Modeling*

182 We developed a mathematical model to analyze relationships among 25(OH)D, 1,25(OH)$_2$D, and
183 24,25(OH)$_2$D. See Table 1 for definitions of model parameters. For the purpose of fitting curves
184 to model our clinical trial data, we estimated model parameters using an iterative trial and error
185 approach.

186 The observed sigmoid curve expressing the concentration of total 24,25(OH)$_2$D as a function of
187 total 25(OH)D was fitted by an equation with the form of Equation (1):

188 $$(1)\quad S(24,25) = \frac{(\frac{W_{24}}{L_{24}})e^{aS(25)}}{1+\frac{e^{aS(25)}}{L_{24}}}$$

189 where S(25) and S(24,25) represent levels of 25(OH)D and 24,25(OH)$_2$D, respectively; W_{24} and
190 L_{24} represent analogs of the maximal velocity and Michaelis-Menten constant for 24-
191 hydroxylase enzyme, respectively, with 25(OH)D as substrate; α is a model parameter to
192 facilitate fitting the equation to the observed data.

193 The model assumes that 24,25(OH)$_2$D is cleared by a first order process with a rate constant of
194 *m(24,25)* [Equation (1a)]:

195 $$(1a)\quad Rate\ of\ clearance\ of\ 24,25(OH)_2D = m(24,25)\frac{(\frac{W_{24}}{L_{24}})e^{aS(25)}}{1+\frac{e^{aS(25)}}{L_{24}}}$$

196 We hypothesized that the 24-hydroxylase enzyme follows Michaelis-Menten kinetics as
197 described by Equation (2):

$$(2)\ Production\ of\ 24{,}25(OH)_2D = \frac{V24 \times h \times S(25)}{K24 + S(25)}$$

where S(25) represents the level of 25(OH)D; V_{24} and K_{24} represent the maximal velocity and Michaelis-Menten constant for 24-hydroxylase enzyme, respectively, with 25(OH)D as substrate. *h* is a variable function of S(25) that represents 24-hydroxylase activity as a fraction of the maximally induced level of the enzyme observed when 25(OH)D levels are high.

At steady state, the rate of production of 24,25$(OH)_2$D [Equation (2)] is equal to the rate at which 24,25$(OH)_2$D is cleared [Equation (1a)]. Accordingly, the value of *h* can be calculated by Equation (3):

$$(3)\ \ h = m(24{,}25)\frac{(\frac{W24}{L24})e^{aS(25)}}{1+\frac{e^{aS(25)}}{L24}} \div \frac{V24 \times S(25)}{K24 + S(25)}$$

Genetic evidence demonstrates the critical role of CYP24A1-mediated 24-hydroxylation in inactivation of 1,25$(OH)_2$D (26, 27). Homozygosity for loss of function mutations in *CYP24A1* has been reported to cause hypercalcemia – presumably due to excessive levels of 1,25$(OH)_2$D. Since CYP24A1 catalyzes 24-hydroxylation of both 25(OH)D and 1,25$(OH)_2$D, we modified Equation (1a) to yield Equation (4):

$$(4)\ Rate\ of\ clearance\ of\ 1{,}25(OH)_2D = m(1{,}25)\frac{(\frac{W1{,}25}{L1{,}25})e^{aS(1{,}25)}}{1+\frac{e^{aS(1{,}25)}}{L1{,}25}}$$

where *S(1,25)* represents the level of 1,25$(OH)_2$D; $W_{1,25}$ and $L_{1,25}$ represent analogs of the maximal velocity and Michaelis-Menten constant for 24-hydroxylase enzyme, respectively, with 1,25$(OH)_2$D as substrate; α is a model parameter that facilitates fitting the equation to the observed data; and *m(1,25)* is a first-order rate constant analogous to *m(24,25)* in Equation (1a).

Further, we hypothesize that CYP27B1-mediated 1α-hydroxylation of 25(OH)D follows Michaelis-Menten kinetics:

$$(5)\ \ Production\ of\ 1{,}25(OH)_2D = \frac{V1 \times S(25)}{K1+S(25)}$$

where V_1 and K_1 represent the maximal velocity and Michaelis-Menten constant for 1α-hydroxylase, respectively, with 25(OH)D as substrate. Under steady state conditions, the rates of production and metabolic clearance of $1{,}25(OH)_2D$ are equal. Thus, we can combine Equations (4) and (5) to yield Equation (6):

$$(6)\ \ \frac{V1 \times S(25)}{K1+S(25)} = m(1{,}25)\frac{(\frac{W1{,}25}{L1{,}25})e^{aS(1{,}25)}}{1+\frac{e^{aS(1{,}25)}}{L1{,}25}}$$

Solving for *S(1,25)*, we obtain Equation (7):

$$(7)\ S(1{,}25) = \{Ln[S(25)] - Ln\left[m_{1,25} + \frac{S(25)}{K_1}\left(m_{1,25} - \frac{V_1}{W_{1,25}}\right)\right] - Ln\frac{W_{1,25}K_1}{L_{1,25}V_1}\}/a$$

Goodness of fit

We calculated the following metrics in order to evaluate the goodness of fit between our mathematical model and the experimental data:

Sum of squares due to regression: $\boldsymbol{SSR} = \sum(\hat{\boldsymbol{x}}_{\boldsymbol{i}} - \overline{\boldsymbol{x}})^{\boldsymbol{2}}$

Total sum of squares about the mean: $\boldsymbol{SST} = \sum(\boldsymbol{x}_{\boldsymbol{i}} - \overline{\boldsymbol{x}})^{\boldsymbol{2}}$

Sum of squared errors: $\boldsymbol{SSE} = \sum(\boldsymbol{x}_{\boldsymbol{i}} - \hat{\boldsymbol{x}}_{\boldsymbol{i}})^{\boldsymbol{2}}$

Data on goodness of fit is provided in the Results section as appropriate.

Estimating relative 24-hydroxylase activity

Equation (3) expresses relative 24-hydroxylase activity (*h*) as a function of the 25(OH)D level. However, total 25(OH)D levels are affected by inter-individual variation in VDBP levels, a factor which is not included in our model. Accordingly, we replaced 25(OH)D levels by the ratio of 25(OH)D/1,25$(OH)_2$D. The 25(OH)D/1,25$(OH)_2$D ratio is independent of VDBP level and provides an index of free levels of 25(OH)D. To normalize values of this ratio to correspond to values of total 25(OH)D, we first divided individual values of the 25(OH)D/1,25$(OH)_2$D by a normalization factor [the mean value of the 25(OH)D/1,25$(OH)_2$D ratio before administration of VitD3 supplements]. We next converted individual values of the normalized 25(OH)D/1,25$(OH)_2$D ratio to the same units as total 25(OH)D by multiplying by a conversion factor [the mean value of 25(OH)D before administration of VitD3 supplements].

Statistics

A two-sided p-value <0.05 (paired t-test) was taken as the threshold for statistical significance without any correction for multiple comparisons. We pooled all the data before and after VitD3 supplementation for graphing total levels of 1,25$(OH)_2$D and 24,25$(OH)_2$D as a function of total levels of 25(OH)D. Both Pearson and Spearman correlation coefficients were calculated using software provided in Excel.

Study approval

The Clinical Trial Protocol was approved by the University of Maryland Baltimore Institutional Review Board (FWA00007145). Written informed consent was obtained from all participants.

254 **RESULTS**

255 Herein we report results of a secondary analysis of data obtained in our published clinical trial
256 investigating pharmacodynamic nutrient-drug interactions between VitD and canagliflozin (13).
257 We applied mathematical modeling to investigate the effects of VitD3 supplementation on
258 homeostatic regulation of VitD metabolite levels. The details of the mathematical model are
259 summarized in the Methods section.

260 *Interrelationships among 1,25(OH)$_2$D, 24,25(OH)$_2$D, and 25(OH)D*.

261 As reported previously, mean (±SEM) total plasma levels of both 25(OH)D and 24,25(OH)$_2$D
262 increased significantly in response to VitD3 supplementation: from 16.5±1.6 to 44.3±5.5 ng/mL
263 (p=0.0006) for 25(OH)D and from 1.0±0.1 to 4.3±0.6 ng/mL (p=0.0002) for 24,25(OH)$_2$D (13).
264 We observed consistent increases in total levels of 25(OH)D and 24,25(OH)$_2$D (Figs. 1A and
265 1B). In contrast, mean total plasma levels of 1,25(OH)$_2$D did not change in response to VitD3
266 supplements (43.8±3.6 pg/mL versus 44.9±4.1 pg/mL; p=0.7) (Fig. 1C) (13). This observation
267 provides strong evidence of the effectiveness of homeostatic mechanisms regulating levels of
268 1,25(OH)$_2$D. Therefore, we conducted exploratory analyses to further investigate physiological
269 mechanisms mediating this homeostatic regulation.

270 For this analysis, we pooled data on VitD metabolites – including data obtained both before and
271 after VitD3 supplementation (Fig. 2). Although there was no significant correlation between total
272 plasma levels of 1,25(OH)$_2$D and 25(OH)D (Fig. 2A), total plasma levels of 24,25(OH)$_2$D
273 increased as a function of total plasma 25(OH)D levels (Fig. 2B).

274 *A critical role for regulation of 24-hydroxylase activity in homeostatic regulation of 1,25(OH)$_2$D*

275 We considered possible mechanisms that might contribute to the observed sigmoid shape of the
276 curve relating total 24,25$(OH)_2$D levels to total 25(OH)D levels (Fig. 2B). If the 24-hydroxylase
277 enzyme (CYP24A1) followed simple Michaelis-Menten kinetics, one might have predicted that
278 the relationship between plasma levels of 24,25$(OH)_2$D and 25(OH)D would have been
279 described by a hyperbola (Fig. 3A, solid curve) rather than a sigmoid curve (Fig. 3A, dashed
280 curve). The observed sigmoid curve approaches an asymptote at high levels of 25(OH)D – most
281 likely a reflection of the saturability of the 24-hydroxylase enzyme (CYP24A1). What can
282 explain the relative underproduction of 24,25$(OH)_2$D at low levels of 25(OH)D as compared to
283 what would have been predicted by simple Michaelis-Menten kinetics? As suggested by others
284 (18, 23, 28), we hypothesized that expression of 24-hydroxylase enzyme is regulated, with low
285 24-hydroxylase activity occurring when 25(OH)D levels are low and higher 24-hydroxylase
286 activity when 25(OH)D levels are high. We applied mathematical modeling (see Methods
287 section) to provide quantitative estimates of the relationship between activity of the 24-
288 hydroxylase enzyme and 25(OH)D levels (Fig. 3C). Our model suggests that 24-hydroxylase
289 activity achieves a maximum when 25(OH)D levels exceed 50 ng/mL. In contrast, VitD
290 deficiency is associated with suppression of 24-hydroxylase activity– achieving a minimum
291 corresponding to ~90% suppression when 25(OH)D levels are less than 10-20 ng/mL. Our
292 mathematical model provides estimates of 24-hydroxylase activity as a function of 25(OH)D
293 levels (Fig. 3C). The data points in Fig. 2A demonstrate substantial "scatter" around the modeled
294 curve. We hypothesize that the ~3-fold range of inter-individual variation in levels of VitD
295 binding protein (VDBP) (29) may account for the observed 3.4-fold range of total levels of
296 1,25$(OH)_2$D observed in this study, which in turn could account for the observed scatter for data
297 points in the plot of total levels of 1,25$(OH)_2$D versus total levels of 25(OH)D (Fig. 2A).

298 Interestingly, the modeled curve predicts that levels of 1,25$(OH)_2$D begin to decrease slightly for
299 levels of 25(OH)D < ~15-20 ng/mL. This "fall-off" may possibly be related to the fact that the
300 model does not account for development of secondary hyperparathyroidism. If the model
301 specified that low levels of 25(OH)D would trigger increased secretion of PTH and resultant
302 increased 1α-hydroxylation of 25(OH)D, it is likely that the model would predict constant levels
303 of 1,25$(OH)_2$D for lower levels of 25(OH)D.

304 *Validating the model using the goodness of fit*

305 Equation (1) provides a good fit to the observed data as shown by the graph plotting total levels
306 of 24,25$(OH)_2$D as a function of 25(OH)D (Fig. 2B). Goodness of fit is evidenced by the fact
307 that the sum of the squared errors (SSE) is small relative to the total sum of the squares about the
308 mean (SST): SSE/SST = 0.078 (Table 2).

309 Moreover, equation (7) correctly predicts that 1,25$(OH)_2$D levels are not correlated with
310 25(OH)D levels (Fig. 2A). Indeed, the sum of the squared errors (SSE) is approximately equal to
311 the total sum of the squares about the mean (SST): SSE/SST = 1.04 (Table 2). Furthermore, the
312 value of the ratio of the sum of the squares due to regression (SSR) divided by SST = 0.094,
313 suggesting that a horizontal line described by the following equation provides a good fit for the
314 observed data: 1,25$(OH)_2$D = 44.4 pg/mL (i.e., with 44.4 pg/mL being the mean level of
315 1,25$(OH)_2$D).

316 *VitD metabolite ratios are better predictive of clinical VitD status*

317 As noted in the literature, ratios of VitD metabolites are relatively independent of inter-individual
318 variation in VDBP levels (24, 30, 31). For example, the following equations demonstrate that the
319 ratio of [1,25$(OH)_2$D]/[24,25$(OH)_2$D] is independent of VDBP levels:

320 (8) $[1,25(OH)_2D]_{total} \approx [1,25(OH)_2D]_{free} \times VDBP_{total} \times K_{1,25}$

321 (9) $[24,25(OH)_2D]_{total} \approx [24,25(OH)_2D]_{free} \times VDBP_{total} \times K_{24,25}$

322 (10) $\frac{[1,25(OH)_2D]_{total}}{[24,25(OH)_2D]_{total}} \approx \frac{[1,25(OH)_2D]_{free}}{[24,25(OH)_2D]_{free}} \times \frac{K_{1,25}}{K_{24,25}}$

323 When the $\frac{[1,25(OH)_2D]_{total}}{[24,25(OH)_2D]_{total}}$ ratio is plotted as a function of total levels of 25(OH)D, this
324 represents a graph of a VDBP-independent variable on the y-axis and a VDBP-dependent
325 variable on the x-axis (Fig. 4A). In contrast, the graph of $\frac{[1,25(OH)_2D]_{total}}{[24,25(OH)_2D]_{total}}$ as a function of
326 $\frac{[25(OH)D]_{total}}{[1,25(OH)_2D]_{total}}$ plots VDBP-independent variables on both axes (Figs. 4B). This approach
327 minimized the contribution of inter-individual variation in VDBP levels, thereby minimizing
328 "scatter" of points in the graph (Fig. 4B). When $\frac{[1,25(OH)_2D]_{total}}{[24,25(OH)_2D]_{total}}$ was plotted as a function of
329 $\frac{[25(OH)D]_{total}}{[1,25(OH)_2D]_{total}}$, the absolute value of the Spearman correlation coefficient was quite high (ρ=-
330 0.94; $p=10^{-10}$) (Fig. 4B). In contrast, the absolute value of the Spearman correlation coefficient
331 was lower (ρ=-0.83; $p=2.2\times10^{-6}$) when $\frac{[1,25(OH)_2D]_{total}}{[24,25(OH)_2D]_{total}}$ was plotted as a function of total levels
332 of 25(OH)D (Fig. 4A).

333 *Modeling VitD Metabolite Ratios*

334 Tang et al. (23) proposed that the ratio of $1,25(OH)_2D/24,25(OH)_2D$ provides an improved
335 assessment of clinical VitD status with a ratio ≥51 suggesting "VitD deficiency" and a ratio of
336 35-50 suggesting "VitD insufficiency". We applied our mathematical model to predict the shape
337 of the curve expressing Tang's VitD metabolite ratio ($1,25(OH)_2D/1,24(OH)_2D$) as a function of
338 total levels of 25(OH)D. Our modeled curve (Fig. 4A) closely resembles the curve included in
339 the publication by Tang et al. (23). Based on our modeled curve, the cutoffs proposed by Tang et

340 al. correspond to total 25(OH)D levels of ~17 ng/mL for "VitD deficiency" and ~21 ng/mL for
341 "VitD insufficiency".

342 Furthermore, our mathematical model provides a good fit to the observed data as shown by the
343 graph plotting total levels of 1,25$(OH)_2$D/24,25$(OH)_2$D as a function of 25(OH)D (Fig. 4A). Two
344 other VitD metabolite ratios have been proposed in the literature: 1,25$(OH)_2$D/25(OH)D (32) and
345 24,25$(OH)_2$D/25(OH)D (24, 30, 31, 33, 34). Our mathematical model predicts that the
346 25(OH)D/1,25$(OH)_2$D ratio [i.e., the reciprocal of the 1,25$(OH)_2$D/25(OH)D ratio proposed in
347 the literature (32)] is a near-linear function of 25(OH)D levels (Fig. 5A); the graph of the
348 24,25$(OH)_2$D/25(OH)D ratio versus 25(OH)D is predicted to be a sigmoid curve (Fig. 5B). The
349 modeled curves for all three VitD metabolite ratios provide good fits to observed data [SSE/SST
350 ratios of 0.49-0.52 (Table 2)].

351 *Correlation of relative 24-hydroxylase activity (h) with VitD metabolite ratios*

352 We pooled our data before and after VitD3 supplementation for each of the three VitD
353 metabolites. We first investigated the correlation of the calculated relative 24-hydroxylase
354 activity (*h*) with total 25(OH)D levels, which gave a Spearman correlation coefficient of ρ=0.85
355 (p=7E-07) (Fig. 6A). We then evaluated correlations with three VitD metabolite ratios. As
356 expected, relative 24-hydroxylase activity (*h*) was perfectly correlated with the
357 25(OH)D/1,25$(OH)_2$D ratio (ρ=1) since this ratio was used in our model to account for the effect
358 of variation in VDBP (Fig. 6B). While 24-hydroxylase activity (*h*) was highly correlated with the
359 1,25$(OH)_2$D/24,25$(OH)_2$D ratio (ρ^2=0.94; p=3E-13) (Fig. 6C), *h* was less well correlated with the
360 24,25$(OH)_2$D/25(OH) ratio (ρ^2=0.67; p=3E-06) (Fig. 6D).

361 *PTH response to VitD3 supplementation and correlation of PTH with indices of VitD status*

362 Although baseline PTH levels were correlated with baseline total 25(OH)D levels before VitD3
363 supplementation (R^2=0.08; p=5E-05), the variance in 25(OH)D accounted for only 8% of the
364 variance in PTH. Furthermore, the slope of the regression line was positive whereas the known
365 physiology predicts that the slope should be negative (Fig. 7A) with PTH levels being higher
366 when 25(OH)D levels are lower. Moreover, baseline PTH levels were not significantly
367 correlated with the baseline 1,25$(OH)_2$D/24,25$(OH)_2$D ratio (R^2=0.008; p=0.63) (Fig. 7B). Even
368 in participants who had received VitD3 supplementation, we observed a wide range for PTH
369 levels (29-85 pg/ml) – suggesting that each participant has an individual setpoint for PTH levels.
370 Therefore, in order to normalize PTH levels relative to each individual's setpoint, we defined a
371 PTH index: i.e., the ratio of the PTH level before VitD3 supplementation divided by the PTH
372 level after VitD3 supplementation. Ten among our 11 participants exhibited PTH indices between
373 0.8-1.2, suggesting that their PTH levels were relatively unaffected by VitD3 supplementation.
374 However, one participant had a PTH index of 1.5 – consistent with a diagnosis of secondary
375 hyperparathyroidism in the VitD deficient state before VitD3 supplementation. The correlation
376 coefficient was higher when we plotted the PTH index as a function of baseline total 25(OH)D
377 levels prior to receiving VitD3 supplementation (R^2=0.23; p=2E-06) (Fig. 7C) compared to the
378 correlation of baseline PTH levels with baseline 25(OH)D levels (R^2=0.08; p=5E-05) (Fig. 7A).
379 Furthermore, the slope was negative for the graph of PTH index as a function of baseline total
380 25(OH)D levels as expected based on the known physiology. We also investigated the correlation
381 of the PTH index with three VitD metabolite ratios. While the correlation coefficient for the
382 correlation of PTH index with 1,25$(OH)_2$D/24,25$(OH)_2$D was 0.60 (R^2=0.36; p=0.0002) (Fig.
383 7D), it was 0.44 for 25(OH)D/1,25$(OH)_2$D ratio (R^2=0.20; p=0.0001) (Fig. 7E) and 0.35 for the
384 24,25$(OH)_2$D/25(OH)D ratio (R^2=0.12; p=2E-06) (Fig. 7F). We conducted a sensitivity analysis

385 by investigating the impact of removing the single participant whose PTH index was outside the
386 range of 0.8-1.2. When we removed data from that participant, the correlation coefficient for the
387 PTH index versus the 1,25$(OH)_2$D/24,25$(OH)_2$D ratio decreased from 0.60 (p=0.0002) to 0.21
388 (p=0.0003) (Fig. 7D). Similar decreases were observed for the values of correlation coefficients
389 for other indices of VitD status (Figs. 7E and 7F).

390 **DISCUSSION**

391 Claude Bernard noted in the 19th century that "*stability of the internal environment (milieu*
392 *intérieur) is a condition for a free and independent life*" (10). Later, in the early 20th century,
393 Walter B. Cannon coined the term "*homeostasis"* to describe mechanisms that maintain the
394 stability of the *milieu intérieur* (9, 10). Because of the critical importance of Ca^{+2} in many
395 biological processes, the "*Wisdom of the Body"* (9, 10) has evolved multiple homeostatic
396 mechanisms to maintain free serum Ca^{+2} levels within a narrow physiological range. Since VitD
397 plays a critical role in mediating intestinal absorption of dietary Ca^{+2}, homeostatic mechanisms
398 also maintain free $1,25(OH)_2D$ within narrow physiological ranges. To maintain stable levels of
399 $1,25(OH)_2D$ when VitD availability is scarce, the body has two defense mechanisms: (1) to
400 increase production of $1,25(OH)_2D$ by increasing PTH-induced 1α-hydroxylation of 25(OH)D
401 (12, 16, 17) and/or (2) to decrease the metabolic clearance of $1,25(OH)_2D$ by suppressing 24-
402 hydroxylase – the enzyme which degrades $1,25(OH)_2D$ and 25(OH)D (14, 15). However, as
403 noted in The Endocrine Society's clinical practice guidelines, VitD deficiency-induced
404 secondary hyperparathyroidism is associated with adverse effects on bone health: VitD-induced
405 secondary hyperparathyroidism has an adverse impact on bone health by increasing "*osteoclastic*
406 *activity thereby creating local foci of bone weakness, which causes a generalized decrease in*
407 *bone mineral density, resulting in osteopenia and osteoporosis*" (17).

408 *Two lines of defense to maintain physiological levels of $1,25(OH)_2D$*

409 Based on our study's inclusion criteria, all research participants met The Endocrine Society's
410 criterion for VitD deficiency [i.e., screening 25(OH)D ≤ 20 ng/mL]. While total 25(OH)D and
411 $24,25(OH)_2D$ levels were increased significantly by VitD3 supplementation, total $1,25(OH)_2D$
412 did not change. Moreover, levels of PTH were within normal limits at baseline and did not

change when supplements were administered to correct the VitD deficiency. These data are consistent with published evidence suggesting that mild-moderate VitD deficiency may not trigger secondary hyperparathyroidism while secondary hyperparathyroidism is a characteristic feature of severe VitD deficiency [25(OH)D <10-12 ng/mL] (35-37).

The published literature contains many graphs displaying PTH levels as a function of total 25(OH)D (35, 38-41). In general, these graphs depict an increase in mean PTH levels as 25(OH)D levels decrease with an inflection point at total 25(OH)D levels in the range between 20-30 ng/mL (37). However, individual data points scatter widely above and below the mean values for PTH. If one focuses on mean data, one might conclude that all individuals are gradually becoming increasingly hyperparathyroid as total 25(OH)D decreases. However, detailed analysis of the data suggests an alternative interpretation. If one examines data points corresponding to 25(OH)D levels in the range of 10-20 ng/mL, the vast majority of individual data points span the same range of PTH levels even as 25(OH)D levels decrease. However, the number of outliers (i.e., elevated PTH levels) begins to increase as 25(OH)D levels decrease below ~20 ng/mL. We interpret this observation as suggesting that there is considerable inter-individual variation in the setpoint for developing secondary hyperparathyroidism. When 25(OH)D levels fall below ~10 ng/mL, there is a substantial increase in both the mean level of PTH and the percentage of individuals with secondary hyperparathyroidism. Although the explanation of the shape of the graph is not entirely clear, we hypothesize that inter-individual variation in VDBP levels may be an important contributor. Individuals with high VDBP levels are predicted to have lower free 25(OH)D levels at any given level of total 25(OH)D. Thus, such individuals with high VDBP levels would be predicted to develop secondary hyperparathyroidism at higher levels of total 25(OH)D. Accordingly, we hypothesize that VDBP-

436 independent indices of VitD status would better predict development of secondary
437 hyperparathyroidism. Tang et al provided data suggesting that the 1,25$(OH)_2$D/24,25$(OH)_2$D
438 ratio >100 is associated with an increased risk of elevated PTH level. Our data are consistent
439 with the hypothesis that the 1,25$(OH)_2$D/24,25$(OH)_2$D ratio may be better correlated with
440 secondary hyperparathyroidism as compared to other indices of VitD status such as the total
441 25(OH)D level.

442 The absence of secondary hyperparathyroidism in our participants with mild-moderate VitD
443 deficiency inspired us to investigate what other homeostatic mechanisms maintained
444 1,25$(OH)_2$D in the normal range. Analysis of our data demonstrated that the correlation between
445 25(OH)D and 24,25$(OH)_2$D levels was defined by a sigmoid curve rather than a hyperbola.
446 Based on this observation, we hypothesized that 24-hydroxylase expression is regulated, and we
447 designed a mathematical model to test our hypothesis. Our model demonstrates that 24-
448 hydroxylase activity achieves a minimum (~90% suppression) when 25(OH)D levels <10-20
449 ng/mL. Thus, in mild-moderate VitD deficiency, the body suppresses 24-hydroxylation to
450 preserve 1,25$(OH)_2$D from degradation and this mechanism provides the first line of defense
451 against VitD deficiency. Interestingly, viewed from a different perspective, high levels of
452 25(OH)D are associated with increased 24-hydroxylase activity, which provides a major defense
453 against VitD toxicity. In the absence of secondary hyperparathyroidism, it is possible that mild-
454 moderate VitD deficiency may not represent an absolute requirement for treatment with VitD
455 supplements if the treatment objective is to promote bone health. On the other hand, recent
456 publications have suggested that 24,25$(OH)_2$D exerts a direct effect to promote healing of bone
457 fractures (42-44). In other words, whether or not mild-moderate VitD deficiency increases the

458 risk of bone fracture, it has been proposed that adequate levels of 24,25$(OH)_2$D may promote
459 healing of bone fractures.

460 Considerable controversy exists with respect to the overall health impact of VitD status and VitD
461 supplementation in the general population (45-48). Published literature demonstrates that severe
462 VitD deficiency triggers secondary hyperparathyroidism, which in turn induces 1α-hydroxylation
463 – thereby increasing the rate of 1,25$(OH)_2$D biosynthesis (16, 35). Because secondary
464 hyperparathyroidism is not triggered unless VitD deficiency becomes severe [e.g., 25(OH)D
465 <10-12 ng/mL] or if 1α-hydroxylation is impaired as in chronic kidney disease, this mechanism
466 provides the second line of defense against VitD deficiency. Secondary hyperparathyroidism is
467 associated with adverse effects on bone health. This provides a strong rationale for treatment
468 with VitD supplements. We propose two diagnostic terms to reflect clinical differences between
469 these two scenarios. "Sub-clinical VitD deficiency" describes a clinical condition when only the
470 first line of defense (suppression of 24-hydroxylase) has been triggered. "Overt VitD deficiency"
471 describes a clinical condition when both lines of defense are triggered (i.e., suppression of 24-
472 hydroxylase plus secondary hyperparathyroidism). This is consistent with conclusions of a
473 scientific workshop sponsored by the National Kidney Foundation in 2018, which suggested that
474 in patients with chronic kidney disease, 25(OH)D levels of <15 ng/mL require VitD treatment
475 and in the range of 15-20 ng/mL, require treatment only if there is evidence of secondary
476 hyperparathyroidism (22).

477 Which molecular mechanism(s) mediate homeostatic regulation of 24-hydroxylase activity?
478 Expression of the *CYP24A1* gene (the gene encoding 24-hydroxylase enzyme) is reported to be
479 increased by 1,25$(OH)_2$D and FGF23 but decreased by PTH (49). However, mean levels of total
480 1,25$(OH)_2$D, FGF23, and PTH did not change in response to VitD3 supplementation in our

481 clinical trial (13). Taken at face value, these observations suggest that regulation of 24-
482 hydroxylase activity may be mediated by factors other than levels of 1,25(OH)$_2$D, FGF23, or
483 PTH. Nevertheless, it remains possible that regulation of 24-hydroxylase activity is sensitive to
484 extremely small changes in levels of 1,25(OH)$_2$D, FGF23, or PTH, which were not captured in
485 our study. Furthermore, all three hormones exhibit circadian variation (50-52). Since we obtained
486 blood samples at only one time of day, we cannot exclude the possibility that the relevant
487 biomarker(s) might require measurements of circulating levels integrated over a 24-hour period.
488 In any case, additional research will be required to answer this interesting question.

489 *Implications for clinical diagnosis of VitD deficiency*

490 Although the Endocrine Society's clinical practice guidelines recommend a "one-size-fits-all"
491 approach based on measurements of total levels of 25(OH)D (17), this approach does not
492 account for the substantial inter-individual variation in levels of VDBP that limits the
493 applicability of this approach. Whereas the usual clinical assays primarily reflect protein-bound
494 levels of VitD metabolites, it is the free levels (i.e., not bound to protein) that are biologically
495 relevant (53). This provides a strong rationale for a *precision diagnostics* approach wherein
496 diagnostic criteria for VitD deficiency are adjusted for each individual based on that person's
497 circulating level of VDBP. Other factors may also be relevant: for example, individual setpoints
498 for PTH secretion and an individual's sensitivity to biological actions of PTH (54). These
499 considerations raise challenging questions about how best to implement a precision diagnostics
500 approach to diagnose VitD deficiency and secondary hyperparathyroidism. Others have
501 suggested the potential value of using a tailored approach to assess VitD status and to guide
502 decisions about the need for VitD supplementation (55). In clinical endocrinology practice,
503 deficiency states are frequently diagnosed by documenting the activation of compensatory

504 homeostatic mechanisms. For example, hypothyroidism is diagnosed by documenting elevated
505 levels of TSH. Conversely, hyperthyroidism is diagnosed by documenting suppression of TSH
506 levels (20). By basing diagnoses on whether the body's homeostatic responses have been
507 triggered, physicians implicitly rely on Cannon's concept of the "*wisdom of the body"* to
508 diagnose hormonal status. Following these precedents, one might base the diagnosis of VitD
509 deficiency on documenting the activation of the relevant homeostatic mechanisms – e.g.,
510 suppression of 24-hydroxylase activity. However, it is challenging to base the diagnosis solely on
511 measuring total 24,25$(OH)_2$D levels because of the confounding influence of inter-individual
512 variation in VDBP levels. The observed threefold inter-individual variation in levels of VDBP
513 (29) is predicted to cause a three-fold inter-individual variation in total levels of 24,25$(OH)_2$D
514 even in individuals with identical levels of free 24,25$(OH)_2$D. Fortunately, VitD metabolite ratios
515 are known to be independent of VDBP levels (24). Tang et al. (23) have advocated the use of the
516 1,25$(OH)_2$D/24,25$(OH)_2$D ratio for this purpose. As confirmed by our mathematical model (Fig.
517 4A), VitD deficiency is associated with a dramatic increase in the 1,25$(OH)_2$D/24,25$(OH)_2$D
518 ratio as a consequence of the marked suppression of 24-hydroxylase activity induced by VitD
519 deficiency. By providing an index of the level of 24-hydroxylase activity, the
520 1,25$(OH)_2$D/24,25$(OH)_2$D ratio provides a highly sensitive index of clinical VitD status.
521 Furthermore, because of the extremely high correlation between the 1,25$(OH)_2$D/24,25$(OH)_2$D
522 ratio and the 25(OH)D/1,25$(OH)_2$D ratio (Fig. 4B), it seems likely that the
523 25(OH)D/1,25$(OH)_2$D ratio might also provide a useful clinical assessment of VitD status. This
524 latter ratio is based on two widely available assays [25(OH)D and 1,25$(OH)_2$D] whereas the
525 1,25$(OH)_2$D/24,25$(OH)_2$D ratio requires an assay for 24,25$(OH)_2$D, which is currently less
526 widely available and more expensive. Different VitD metabolite ratios have been suggested for

527 assessment of VitD status and some studies have investigated their predictive value for hard
528 clinical endpoints e.g., risk of bone fracture (31, 33). The 24,25$(OH)_2$D/25(OH)D ratio has
529 gained attention as a clinically informative substitute for total plasma 25(OH)D for assessment of
530 VitD status. Furthermore, the scientific workshop sponsored by the National Kidney Foundation
531 proposed that the 24,25$(OH)_2$D/25(OH)D ratio might be particularly useful in patients with CKD
532 as a surrogate for activity of 24-hydroxylase, as in this patient population 1α-hydroxylation of
533 25(OH)D is impaired (22).

534 *Interindividual variation in PTH levels*

535 Even in VitD-replete participants being treated with VitD3 supplements, we observed a wide
536 range of PTH levels (29-85pg/mL). Furthermore, mean levels of PTH were not significantly
537 affected by administration of VitD3 supplements in our study (47.5±4.8 pg/mL before and
538 48.4±5.1 pg/mL after VitD3 supplementation). As suggested by others (56), interindividual
539 variation in PTH levels may reflect variation in the setpoint for PTH secretion. Variation in
540 dietary calcium intake may also affect PTH levels (57). These considerations create major
541 challenges in how to interpret an individual measurement of PTH. We, therefore, assessed the
542 response of PTH to VitD3 supplementation as an indication of whether a participant exhibited
543 secondary hyperparathyroidism due to VitD deficiency. While one participant exhibited a ~34%
544 decrease in PTH level in response to VitD3 supplementation, the other participants did not
545 exhibit significant suppression of PTH levels in response to VitD3 supplementation. We
546 compared the performance of various indices of VitD status as predictors of secondary
547 hyperparathyroidism. Among the indices of VitD status, the 1,25$(OH)_2$D/24,25$(OH)_2$D ratio was
548 the most highly correlated with our index of secondary hyperparathyroidism (R^2=0.36;
549 p=0.0002). However, none of the indices of VitD status accounted for more than 36% of the

550 variance in our index of secondary hyperparathyroidism – most likely, because only one of our
551 11 participants had any evidence suggestive of secondary hyperparathyroidism. In contrast, the
552 1,25$(OH)_2$D/24,25$(OH)_2$D ratio was highly correlated (ρ^2=-0.94; p=3E-13) with relative 24-
553 hydroxylase activity as calculated by our mathematical model – accounting for 94% of the
554 variance in relative 24-hydroxylase activity. Other indices were less well correlated:
555 24,25$(OH)_2$D/25(OH)D (ρ^2=0.67; p=3E-06) and total 25(OH)D (ρ^2=0.72; p=7E-07).

556 *Study design: strengths and limitations*

557 The study was designed as a crossover study to enable paired statistical analyses comparing data
558 obtained before versus after administration of VitD3 supplements. To minimize the impact of
559 circadian rhythms for plasma 1,25$(OH)_2$D, PTH, and FGF23 (50-52), all blood samples were
560 obtained at the same time of day (~7:00 am). Using LC-MS/MS-based assays of VitD
561 metabolites (Quest Diagnostics and Heartland Assays), we did not detect metabolites of VitD2 in
562 any of our participants. The absence of VitD2 metabolites simplified data interpretation by
563 avoiding potential issues related to differences between VitD2 and VitD3 (58). Data on levels of
564 25(OH)D and 24,25$(OH)_2$D were provided by Heartland Assays – a company that specializes in
565 applying liquid chromatography and mass spectroscopy (LC-MS/MS) to conduct scientifically
566 rigorous and reproducible assays of VitD metabolites. Our novel mathematical model provided
567 quantitative estimates of *in vivo* 24-hydroxylase activity and represents another strength of the
568 study. Furthermore, while previous publications provide data on one or another ratio of VitD
569 metabolites (22, 24, 30, 31), our analysis compares the predictive value of three VitD metabolite
570 ratios: 1,25$(OH)_2$D/24,25$(OH)_2$D; 25(OH)D/1,25$(OH)_2$D; and 24,25$(OH)_2$D/25(OH)D.

571 In addition to these strengths of our study design, the study had important limitations. Although
572 our original study design proposed to study 25 participants, the impact of the COVID-19

573 pandemic necessitated a decrease in the sample size to 11 participants. Limitations associated
574 with the relatively small sample size are partially mitigated by our efforts to assure scientific
575 rigor and reproducibility of the primary data – e.g., the enhanced statistical power provided by
576 conducting paired statistical comparisons. Accordingly, many of our analyses [e.g., VitD-induced
577 changes in 25(OH)D and 24,25$(OH)_2$D] demonstrated high levels of statistical significance.
578 Other analyses [e.g., comparisons for 1,25$(OH)_2$D and PTH] demonstrated essentially identical
579 mean values before and after VitD3 supplementation. Based on clinical guidelines of The
580 Endocrine Society, all of our participants exhibited some degree of VitD deficiency. However,
581 only one participant exhibited more severe VitD deficiency accompanied by secondary
582 hyperparathyroidism. Additional research will be required to better understand VitD homeostatic
583 mechanisms in patients with severe VitD deficiency.

584 Finally, this study was designed as an outpatient study with participants free to eat *ad libitum*.
585 Day-to-day variation in dietary intake of calcium and phosphate may have increased variation in
586 measurements of various endpoints – e.g., PTH or FGF23. Furthermore, since our study design
587 did not include data on dietary intake, our analysis could not investigate dietary factors as
588 covariates. We have offered some tentative hypotheses related to the necessity of VitD
589 supplements in overt VitD deficiency as compared to the possible optional nature of VitD
590 supplements in sub-clinical VitD deficiency. However, we acknowledge that the present study
591 does not provide sufficient data to draw rigorous evidence-based conclusions with respect to
592 treatment recommendations. Our small pilot study is based on biomarker data rather than hard
593 clinical outcomes. Future research will be required to address these important clinical questions.
594 Nevertheless, we believe it is valuable to offer hypotheses based on implications derived from
595 consideration of underlying physiology and pathophysiology.

596 **Acknowledgements**

597 The authors gratefully acknowledge research funding provided by NIDDK and the NIH Office of
598 Dietary Supplements: R01DK118942, R01DK118942-02S1, and T32DK098107. We are also
599 grateful to the staff at University of Maryland's Amish Research Clinic and to the members of the
600 Old Order Amish Community in Lancaster, PA who participated in this clinical trial.

601 **Data Availability**

602 Primary data will be made available upon request to qualified academic investigators for research
603 purposes under a Data Transfer Agreement to protect research participants' confidential
604 information.

605 **Table 1. Parameters of the mathematical model.**

Model parameters	Definitions
α	A model parameter to facilitate fitting the equation to the observed data
h	Relative 24-hydroxylase activity
K1	Michaelis-Menten constant for 1α-hydroxylase with 25(OH)D as substrate
$\mathbf{K_{24}}$	Michaelis-Menten constant for 24-hydroxylase enzyme with 25(OH)D as substrate (to fit hyperbolic curve)
$\boldsymbol{L_{1,25}}$	Analog of Michaelis-Menten constant for 24-hydroxylase enzyme with $1,25(OH)_2D$ as substrate (to fit sigmoid curve)
$\mathbf{L_{24}}$	Analog of Michaelis-Menten constant for 24-hydroxylase enzyme with 25(OH)D as substrate (to fit sigmoid curve)
m(1,25)	First order rate constant for metabolic clearance of $1,25(OH)_2D$
m(24,25)	First order rate constant for metabolic clearance of $24,25(OH)_2D$
S(1,25)	$1,25(OH)_2D$ concentration
S(24,25)	$24,25(OH)_2D$ concentration
S(25)	25(OH)D concentration
V1	Maximal velocity for 1α-hydroxylase with 25(OH)D as substrate
$\mathbf{V_{24}}$	Maximal velocity for 24-hydroxylase with 25(OH)D as substrate (to fit hyperbolic curve)
$\boldsymbol{W_{1,25}}$	Maximal velocity for 24-hydroxylase with $1,25(OH)_2D$ as substrate (to fit sigmoid curve)
$\mathbf{W_{24}}$	Maximal velocity for 24-hydroxylase with 25(OH)D as substrate (to fit sigmoid curve)

606

607 **Table 2. Goodness of fit for mathematical model equations**. The Table includes metrics for the
608 goodness of fit for the modeling equations for 1,25(OH)$_2$D (Fig. 2A) and 24,25(OH)$_2$D (Fig. 2B)
609 as well as the goodness of fit for modeling of three VitD metabolite ratios (Figs. 4A, 5A, and
610 5B).

	24,25(OH)D	1,25(OH)$_2$D	1,25(OH)$_2$D/ 24,25(OH)$_2$D	25(OH)D/ 1,25(OH)$_2$D	24,25(OH)$_2$D/ 25(OH)D
Sum of squares due to regression (SSR) [a]	113	315	809	3.37	0.150
Total sum of squares about mean (SST) [b]	105	3341	849	3.22	0.151
Sum of squared errors (SSE) [c]	8.2	3483	412	1.66	0.079
Ratio of SSE/SST	0.078	1.04	0.49	0.52	0.52
Ratio of SSR/SST	1.08	0.094	0.95	1.05	0.995

611 [a] $\boldsymbol{SSR} = \sum(\hat{\boldsymbol{x}}_{\boldsymbol{i}} - \overline{\boldsymbol{x}})^{\boldsymbol{2}}$

612 [b] $\boldsymbol{SST} = \sum(\boldsymbol{x}_{\boldsymbol{i}} - \overline{\boldsymbol{x}})^{\boldsymbol{2}}$

613 [c] $\boldsymbol{SSE} = \sum(\boldsymbol{x}_{\boldsymbol{i}} - \hat{\boldsymbol{x}}_{\boldsymbol{i}})^{\boldsymbol{2}}$

614 Where $\boldsymbol{x}_{\boldsymbol{i}}$ represents individual observed total levels of VitD metabolites, $\hat{\boldsymbol{x}}_{\boldsymbol{i}}$ represents individual
615 predicted total levels of VitD metabolites, and $\overline{\boldsymbol{x}}$ represents the mean of observed total levels of
616 VitD metabolites.

617 **FIGURE LEGENDS**

618 **Figure 1. Impact of VitD3 supplementation on total levels of VitD metabolites.** Healthy
619 participants (N=11) were recruited based on meeting the Endocrine Society's criterion of VitD
620 deficiency [25(OH)D ≤20 ng/mL]. Total levels of VitD metabolites were assayed before and after
621 participants received VitD3 supplements (13): 25(OH)D (panel A), 24,25$(OH)_2$D (panel B), and
622 1,25$(OH)_2$D (panel C). Data are presented as means ± SEM; p-values were calculated using a
623 two-tailed t-test for paired data.

624

625 **Figure 2. Total levels of 1,25$(OH)_2$D and 24,25$(OH)_2$D as a function of total levels of**
626 **25(OH)D.** Panels A and B present pooled data for individual participants when they were VitD
627 deficient (gray circles) and after they received VitD3 supplements (black circles). 1,25$(OH)_2$D
628 (panel A) and 24,25$(OH)_2$D (panel B) are plotted as a function of total levels of 25(OH)D. The
629 text box in panel B presents the Spearman correlation coefficient (ρ). The curves represent the
630 equations derived from our mathematical model: equation (1) in Panel A and equation (7) in
631 Panel B. Values of parameters for Equation (1): W_{24}=8 ng/mL; L_{24}=40 ng/mL; and α=0.1. Values
632 for parameters for Equation (7): $W_{1,25}$=40 ng/mL; $L_{1,25}$=60 ng/mL; V_1=40; K=60 ng/mL; α=0.1;
633 and $m_{1,25}$=1.

634

635 **Figure 3. Assumptions underlying mathematical model: regulation of 24-hydroxylase**
636 **activity in response to clinical VitD status.** Panel A depicts curves corresponding to equations
637 (1) and (2) [sigmoid and hyperbola, respectively]. Panel B depicts a family of hyperbolas
638 [equation (2)] corresponding to varying degrees of induction from 10-100% of maximal

639 induction of 24-hydroxylase activity. Panel C depicts equation (3), which is the fractional
640 induction of 24-hydroxylase activity relative to the maximal level of induction as a function of
641 25(OH)D. Values of parameters for Equation (1): W_{24}=8 ng/mL; L_{24}=40 ng/mL; and α=.0.1.
642 Values for parameters for Equation (2): V_{24}=10 and K_{24}=20 ng/mL. Values of parameters for
643 Equation (3) m(24,25)=1; other parameters the same as for Equations (1) and (2).

644

645 **Figure 4. The 1,25(OH)$_2$D/24,25(OH)D and 25(OH)D/1,25(OH)$_2$D ratios reflect clinical**
646 **VitD status.** The graphs summarize data from individual participants when they were VitD
647 deficient (gray circles) and after they received VitD3 supplements (black circles). Panel A depicts
648 the 1,25(OH)$_2$D/24,25(OH)$_2$D ratio as a function of total 25(OH)D. The modeled curve was
649 calculated as the ratio of modeled values for 1,25(OH)$_2$D [equation (7)] divided by modeled
650 values of 24,25(OH)$_2$D [equation (1)]. Panel B depicts 1,25(OH)$_2$D/24,25(OH)$_2$D ratio as a
651 function of 25(OH)D/1,25(OH)$_2$D ratio. The fitted curves were calculated by GraphPad Prism
652 software. Text boxes indicate Spearman correlation coefficients and p-values for the correlations.

653

654 **Figure 5. VitD metabolite ratios [25(OH)D/1,25(OH)$_2$D and 24,25(OH)$_2$D/25(OH)D] as a**
655 **function of the total levels of 25(OH)D.** The graphs summarize data from individual
656 participants when they were VitD deficient (gray circles) and after they received VitD3
657 supplements (black circles). Panel A depicts the 25(OH)D/1,25(OH)$_2$D ratio as a function of total
658 25(OH)D. The modeled curve was calculated as a linear regression using GraphPad Prism
659 software. Panel B depicts 24,25(OH)$_2$D/25(OH)D ratio as a function of 25(OH)D. The modeled

660 curve was calculated as modeled values for 24,25$(OH)_2$D [equation (1)] divided by assumed
661 values of 25(OH)D.

662

663 **Figure 6. Correlation between relative 24-hydroxylase activity (*h*) and indices of VitD**
664 **status**. Panels A-D present pooled data when participants were VitD deficient (gray circles) and
665 after they received VitD3 supplementation (black circles). The text boxes below the panels
666 present two Spearman correlation coefficients and two p-values. The first bullet points
667 correspond to the correlation between 24-hydroxylase and each of the VitD status indices at
668 baseline before participants received VitD3 supplementation. The second bullet points
669 correspond to the correlation between 24-hydroxylase and each of the VitD status indices based
670 on the pooled data (both before and after VitD3 supplementation). The curves in the graphs were
671 based on modeling of the pooled data.

672

673 **Figure 7. Correlation between PTH and different indices of VitD status**. Panels A and B
674 depict correlations of baseline PTH levels with baseline total 25(OH)D (panel A) or baseline
675 1,25$(OH)_2$D/24,25$(OH)_2$D ratio (panel B) before participants received VitD3 supplementation.
676 Panel C depicts the correlation between the PTH index (PTH level before VitD3 supplementation
677 divided by PTH level after VitD3 supplementation) and baseline total 25(OH)D. Panels D, E, and
678 F depict correlations between the PTH index and other indices of VitD status:
679 1,25$(OH)_2$D/24,25$(OH)_2$D ratio (panel D), 25(OH)D/1,25$(OH)_2$D ratio (panel E), and
680 24,25$(OH)_2$D/25(OH)D ratio (panel F). The solid black lines correspond to least-squares fits for
681 all 11 data points. Gray dotted lines in panels C-F correspond to a sensitivity analysis conducted

682 by removing the participant who had the highest $1,25(OH)_2D/24,25(OH)_2D$ ratio and PTH index.

683 That participant is shown by a gray square in the panels C-F. The text boxes below panels C-F

684 present equations and p-values corresponding to the gray dotted lines.

685 **REFERENCES**

686

687 1. Christakos S, Dhawan P, Porta A, Mady LJ, and Seth T. Vitamin D and intestinal calcium
688 absorption. *Mol Cell Endocrinol.* 2011;347(1-2):25-9.
689 2. Fleet JC. Vitamin D-Mediated Regulation of Intestinal Calcium Absorption. *Nutrients.*
690 2022;14(16).
691 3. Christakos S, Li S, De La Cruz J, Shroyer NF, Criss ZK, Verzi MP, et al. Vitamin D and
692 the intestine: Review and update. *J Steroid Biochem Mol Biol.* 2020;196:105501.
693 4. Fleet JC. The role of vitamin D in the endocrinology controlling calcium homeostasis.
694 *Mol Cell Endocrinol.* 2017;453:36-45.
695 5. Chick HD, E.G.; Hume, M.; Mackay, H.M.M.; Smith, H.H.; Wimberger, H. The
696 aetiology of rickets in infants: Prophylactic and curative observations at the Vienna
697 University Kinderklinik. *The Lancet.* 1922:7-11.
698 6. Rajakumar K. Vitamin D, cod-liver oil, sunlight, and rickets: a historical perspective.
699 *Pediatrics.* 2003;112(2):e132-5.
700 7. Miller WL, and Imel EA. Rickets, Vitamin D, and Ca/P Metabolism. *Horm Res Paediatr.*
701 2022;95(6):579-92.
702 8. Bikle DD. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E,
703 et al. eds. *Endotext*. South Dartmouth (MA): MDText.com, Inc. Copyright © 2000-2023,
704 MDText.com, Inc.; 2000.
705 9. Cannon WB. *The wisdom of the body.* Norton and Company Limited, W. W.; 1963.
706 10. Davies KJ. Adaptive homeostasis. *Mol Aspects Med.* 2016;49:1-7.

707 11. Holick MF. Vitamin D status: measurement, interpretation, and clinical application. *Ann*
708 *Epidemiol.* 2009;19(2):73-8.
709 12. Young K, Beggs MR, Grimbly C, and Alexander RT. Regulation of 1 and 24
710 hydroxylation of vitamin D metabolites in the proximal tubule. *Exp Biol Med*
711 *(Maywood).* 2022;247(13):1103-11.
712 13. Shahidzadeh Yazdi Z, Streeten EA, Whitlatch HB, Montasser ME, Beitelshees AL, and
713 Taylor SI. Vitamin D deficiency increases vulnerability to canagliflozin-induced adverse
714 effects on 1,25-dihydroxyvitamin D and PTH. *J Clin Endocrinol Metab.* 2023.
715 14. Jones G, Strugnell SA, and DeLuca HF. Current understanding of the molecular actions
716 of vitamin D. *Physiol Rev.* 1998;78(4):1193-231.
717 15. Jones G, Prosser DE, and Kaufmann M. 25-Hydroxyvitamin D-24-hydroxylase
718 (CYP24A1): its important role in the degradation of vitamin D. *Arch Biochem Biophys.*
719 2012;523(1):9-18.
720 16. Brenza HL, Kimmel-Jehan C, Jehan F, Shinki T, Wakino S, Anazawa H, et al. Parathyroid
721 hormone activation of the 25-hydroxyvitamin D3-1alpha-hydroxylase gene promoter.
722 *Proc Natl Acad Sci U S A.* 1998;95(4):1387-91.
723 17. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et
724 al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society
725 clinical practice guideline. *J Clin Endocrinol Metab.* 2011;96(7):1911-30.
726 18. Tanaka Y, and DeLuca HF. Stimulation of 24,25-dihydroxyvitamin D3 production by
727 1,25-dihydroxyvitamin D3. *Science.* 1974;183(130):1198-200.

728 19. Tahaka Y, Lorenc RS, and DeLuca HF. The role of 1,25-dihydroxyvitamin D3 and
729 parathyroid hormone in the regulation of chick renal 25-hydroxyvitamin D3-24-
730 hydroxylase. *Arch Biochem Biophys.* 1975;171(2):521-6.
731 20. Ladenson PW. Diseases of the thyroid gland. *Clin Endocrinol Metab.* 1985;14(1):145-73.
732 21. Raff H, and Carroll T. Cushing's syndrome: from physiological principles to diagnosis
733 and clinical care. *J Physiol.* 2015;593(3):493-506.
734 22. Melamed ML, Chonchol M, Gutiérrez OM, Kalantar-Zadeh K, Kendrick J, Norris K, et
735 al. The Role of Vitamin D in CKD Stages 3 to 4: Report of a Scientific Workshop
736 Sponsored by the National Kidney Foundation. *Am J Kidney Dis.* 2018;72(6):834-45.
737 23. Tang JCY, Jackson S, Walsh NP, Greeves J, and Fraser WD. The dynamic relationships
738 between the active and catabolic vitamin D metabolites, their ratios, and associations with
739 PTH. *Sci Rep.* 2019;9(1):6974.
740 24. Ginsberg C, Hoofnagle AN, Katz R, Becker JO, Kritchevsky SB, Shlipak MG, et al. The
741 Vitamin D Metabolite Ratio Is Independent of Vitamin D Binding Protein Concentration.
742 *Clin Chem.* 2021;67(2):385-93.
743 25. Biancuzzo RM, Clarke N, Reitz RE, Travison TG, and Holick MF. Serum concentrations
744 of 1,25-dihydroxyvitamin D2 and 1,25-dihydroxyvitamin D3 in response to vitamin D2
745 and vitamin D3 supplementation. *J Clin Endocrinol Metab.* 2013;98(3):973-9.
746 26. Schlingmann KP, Kaufmann M, Weber S, Irwin A, Goos C, John U, et al. Mutations in
747 CYP24A1 and idiopathic infantile hypercalcemia. *N Engl J Med.* 2011;365(5):410-21.
748 27. Streeten EA, Zarbalian K, and Damcott CM. CYP24A1 mutations in idiopathic infantile
749 hypercalcemia. *N Engl J Med.* 2011;365(18):1741-2; author reply 2-3.

750 28. Batacchi Z, Robinson-Cohen C, Hoofnagle AN, Isakova T, Kestenbaum B, Martin KJ, et
751 al. Effects of Vitamin D(2) Supplementation on Vitamin D(3) Metabolism in Health and
752 CKD. *Clin J Am Soc Nephrol.* 2017;12(9):1498-506.
753 29. Robinson-Cohen C, Zelnick LR, Hoofnagle AN, Lutsey PL, Burke G, Michos ED, et al.
754 Associations of Vitamin D-Binding Globulin and Bioavailable Vitamin D Concentrations
755 With Coronary Heart Disease Events: The Multi-Ethnic Study of Atherosclerosis
756 (MESA). *J Clin Endocrinol Metab.* 2017;102(8):3075-84.
757 30. Ahmed LHM, Butler AE, Dargham SR, Latif A, Chidiac OM, Atkin SL, et al. Vitamin
758 D(3) metabolite ratio as an indicator of vitamin D status and its association with diabetes
759 complications. *BMC Endocr Disord.* 2020;20(1):161.
760 31. Ginsberg C, Hoofnagle AN, Katz R, Hughes-Austin J, Miller LM, Becker JO, et al. The
761 Vitamin D Metabolite Ratio Is Associated With Changes in Bone Density and Fracture
762 Risk in Older Adults. *J Bone Miner Res.* 2021;36(12):2343-50.
763 32. Meng L, Su C, Shapses SA, and Wang X. Total and free vitamin D metabolites in patients
764 with primary hyperparathyroidism. *J Endocrinol Invest.* 2022;45(2):301-7.
765 33. Bansal N, Katz R, Appel L, Denburg M, Feldman H, Go AS, et al. Vitamin D Metabolic
766 Ratio and Risks of Death and CKD Progression. *Kidney Int Rep.* 2019;4(11):1598-607.
767 34. Ginsberg C, Katz R, de Boer IH, Kestenbaum BR, Chonchol M, Shlipak MG, et al. The
768 24,25 to 25-hydroxyvitamin D ratio and fracture risk in older adults: The cardiovascular
769 health study. *Bone.* 2018;107:124-30.
770 35. Jesudason D, Need AG, Horowitz M, O'Loughlin PD, Morris HA, and Nordin BE.
771 Relationship between serum 25-hydroxyvitamin D and bone resorption markers in
772 vitamin D insufficiency. *Bone.* 2002;31(5):626-30.

773 36. Jones G. 100 YEARS OF VITAMIN D: Historical aspects of vitamin D. *Endocr Connect.*
774 2022;11(4).
775 37. Rosen CJ, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, et al.
776 IOM committee members respond to Endocrine Society vitamin D guideline. *J Clin*
777 *Endocrinol Metab.* 2012;97(4):1146-52.
778 38. Mendes MM, Hart KH, Lanham-New SA, and Botelho PB. Suppression of Parathyroid
779 Hormone as a Proxy for Optimal Vitamin D Status: Further Analysis of Two Parallel
780 Studies in Opposite Latitudes. *Nutrients.* 2020;12(4).
781 39. Looker AC, and Gunter EW. Hypovitaminosis D in medical inpatients. *N Engl J Med.*
782 1998;339(5):344-5; author reply 5-6.
783 40. Shah S, Chiang C, Sikaris K, Lu Z, Bui M, Zebaze R, et al. Serum 25-Hydroxyvitamin D
784 Insufficiency in Search of a Bone Disease. *J Clin Endocrinol Metab.* 2017;102(7):2321-
785 8.
786 41. Gallagher JC, Jindal PS, and Smith LM. Vitamin D supplementation in young White and
787 African American women. *J Bone Miner Res.* 2014;29(1):173-81.
788 42. Demay MB. The good and the bad of vitamin D inactivation. *J Clin Invest.*
789 2018;128(9):3736-8.
790 43. Martineau C, Kaufmann M, Arabian A, Jones G, and St-Arnaud R. Preclinical safety and
791 efficacy of 24R,25-dihydroxyvitamin D(3) or lactosylceramide treatment to enhance
792 fracture repair. *J Orthop Translat.* 2020;23:77-88.
793 44. Martineau C, Naja RP, Husseini A, Hamade B, Kaufmann M, Akhouayri O, et al. Optimal
794 bone fracture repair requires 24R,25-dihydroxyvitamin D3 and its effector molecule
795 FAM57B2. *J Clin Invest.* 2018;128(8):3546-57.

796 45. Bouillon R, Manousaki D, Rosen C, Trajanoska K, Rivadeneira F, and Richards JB. The
797 health effects of vitamin D supplementation: evidence from human studies. *Nat Rev*
798 *Endocrinol.* 2022;18(2):96-110.
799 46. Cummings SR, and Rosen C. VITAL Findings - A Decisive Verdict on Vitamin D
800 Supplementation. *N Engl J Med.* 2022;387(4):368-70.
801 47. LeBoff MS, Chou SH, Ratliff KA, Cook NR, Khurana B, Kim E, et al. Supplemental
802 Vitamin D and Incident Fractures in Midlife and Older Adults. *N Engl J Med.*
803 2022;387(4):299-309.
804 48. Pfotenhauer KM, and Shubrook JH. Vitamin D Deficiency, Its Role in Health and
805 Disease, and Current Supplementation Recommendations. *J Am Osteopath Assoc.*
806 2017;117(5):301-5.
807 49. Meyer MB, and Pike JW. Mechanistic homeostasis of vitamin D metabolism in the
808 kidney through reciprocal modulation of Cyp27b1 and Cyp24a1 expression. *J Steroid*
809 *Biochem Mol Biol.* 2020;196:105500.
810 50. Blau JE, Bauman V, Conway EM, Piaggi P, Walter MF, Wright EC, et al. Canagliflozin
811 triggers the FGF23/1,25-dihydroxyvitamin D/PTH axis in healthy volunteers in a
812 randomized crossover study. *JCI Insight.* 2018;3(8).
813 51. el-Hajj Fuleihan G, Klerman EB, Brown EN, Choe Y, Brown EM, and Czeisler CA. The
814 parathyroid hormone circadian rhythm is truly endogenous--a general clinical research
815 center study. *J Clin Endocrinol Metab.* 1997;82(1):281-6.
816 52. Kawai M, Kinoshita S, Shimba S, Ozono K, and Michigami T. Sympathetic activation
817 induces skeletal Fgf23 expression in a circadian rhythm-dependent manner. *J Biol Chem.*
818 2014;289(3):1457-66.

819 53. Bikle DD. The Free Hormone Hypothesis: When, Why, and How to Measure the Free
820 Hormone Levels to Assess Vitamin D, Thyroid, Sex Hormone, and Cortisol Status. *JBMR*
821 *Plus.* 2021;5(1):e10418.
822 54. Lemoine S, Figueres L, Bacchetta J, Frey S, and Dubourg L. Calcium homeostasis and
823 hyperparathyroidism: Nephrologic and endocrinologic points of view. *Ann Endocrinol*
824 *(Paris).* 2022;83(4):237-43.
825 55. Bilezikian JP, Formenti AM, Adler RA, Binkley N, Bouillon R, Lazaretti-Castro M, et al.
826 Vitamin D: Dosing, levels, form, and route of administration: Does one approach fit all?
827 *Rev Endocr Metab Disord.* 2021;22(4):1201-18.
828 56. Robinson-Cohen C, Lutsey PL, Kleber ME, Nielson CM, Mitchell BD, Bis JC, et al.
829 Genetic Variants Associated with Circulating Parathyroid Hormone. *J Am Soc Nephrol.*
830 2017;28(5):1553-65.
831 57. Rejnmark L, Vestergaard P, Heickendorff L, and Mosekilde L. Determinants of plasma
832 PTH and their implication for defining a reference interval. *Clin Endocrinol (Oxf).*
833 2011;74(1):37-43.
834 58. Tripathi A, Ansari M, Dandekar P, and Jain R. Analytical methods for 25-hydroxyvitamin
835 D: advantages and limitations of the existing assays. *J Nutr Biochem.* 2022;109:109123.

836


A
25(OH)D
25(OH)D (ng/mL)
100
80
60
40
20
0
44.3 ± 5.5
P=0.0006
16.5 ± 1.6
VitD deficient
VitD supplemented
B
24,25(OH)2D
24,25(OH)2D (ng/mL)
10
8
6
4
2
0
4.3 ± 0.6
P=0.0002
1.0 ± 0.1
VitD deficient
VitD supplemented
C
1,25(OH)2D
1,25(OH)2D (pg/mL)
80
60
40
20
0
43.8 ± 3.6
P=0.7
44.9 ± 4.1
VitD deficient
VitD supplemented


Vitamin D
25(OH)D
1,25(OH)2D
1,24,25(OH)3D
24,25(OH)2D
A
1,25(OH)2D vs. 25(OH)D
1,25(OH)2D (pg/mL)
25(OH)D (ng/mL)
Modeled curve
VitD deficient
VitD sufficient
B
24,25(OH)2D vs. 25(OH)D
24,25(OH)2D (ng/mL)
25(OH)D (ng/mL)
ρ=0.95


A
Sigmoid vs Hyperbola
24,25(OH)2D
Hyperbola
Sigmoid
25(OH)D (ng/mL)
B
Family of Hyperbolas
24-Hydroxylase (%maximal)
100%
75%
50%
25%
10%
25(OH)D (ng/mL)
C
24-Hydroxylase activity
Induction (% maximal)
25(OH)D (ng/mL)


A
1,25(OH)2D/24,25(OH)2D vs.
25(OH)D
ρ=-0.83
p=2.2x10-6
1,25(OH)2D/24,25(OH)2D
25(OH)D (ng/mL)
0
25
50
75
100
125
0
10
20
30
40
50
60
70
80
B
1,25(OH)2D/24,25(OH)2D vs.
25(OH)D/1,25(OH)2D
ρ=-0.94
p=10-10
1,25(OH)2D/24,25(OH)2D
25(OH)D/1,25(OH)2D
0
25
50
75
100
125
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8


A
25(OH)D/1,25(OH)2D vs.
25(OH)D
25(OH)D/1,25(OH)2D
1.8
1.6
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
0
20
40
60
80
25(OH)D (ng/mL)
B
24,25(OH)2D/25(OH)D vs.
25(OH)D
24,25(OH)2D/25(OH)D
0.150
0.125
0.100
0.075
0.050
0.025
0.000
0
20
40
60
80
25(OH)D (ng/mL)



Spearman correlation coefficients:
- **Before VitD3 → 0.51 (p=0.1)**
- **Pooled data → 0.85 (p=7E-07)**



Spearman correlation coefficients:
- **Before VitD3 → 1.00**
- **Pooled data → 1.00**



Spearman correlation coefficients:
- **Before VitD3 → -0.85 (p=0.001)**
- **Pooled data → -0.97 (p=3E-13)**



Spearman correlation coefficients:
- **Before VitD3 → 0.37 (p=0.3)**
- **Pooled data → 0.82 (p=3E-06)**


A
Baseline PTH vs. baseline 25(OH)D
Baseline PTH (pg/mL)
Baseline 25(OH)D (ng/mL)
y = 0.86x + 33
R² = 0.08
p=5E-05
B
Baseline PTH vs. baseline 1,25(OH)2D/24,25(OH)2D
Baseline PTH (pg/mL)
Baseline 1,25(OH)2D/24,25(OH)2D (pg/ng)
y = -0.05x + 50
R² = 0.008
p=0.63
C
PTH index vs. baseline 25(OH)D
PTH index
Baseline 25(OH)D (ng/mL)
y = -0.02x + 1.31
R² = 0.23
p=2E-06
Dotted line:
y = -0.01x + 1.12
R² = 0.18
p=5E-06
D
PTH index vs. baseline 1,25(OH)2D/24,25(OH)2D
PTH index
1,25(OH)2D/24,25(OH)2D (pg/ng)
y = 0.004x + 0.77
R² = 0.36
p=0.0002
Dotted line:
Y = 0.001x + 0.89
R² = 0.04
p=0.0003
E
PTH index vs. baseline 25(OH)D/1,25(OH)2D
PTH index
Baseline 25(OH)D/1,25(OH)2D (ng/pg)
y = -0.55x + 1.22
R² = 0.20
p=0.0001
Dotted line:
Y = 0.23x + 1.04
R²= 0.09
p=7.5E-05
F
PTH index vs. baseline 24,25(OH)2D/25(OH)D
PTH index
Baseline 24,25(OH)2D/25(OH)D
y = -0.05x + 1.27
R² = 0.12
P=2E-06
Dotted line:
y = -0.001x + 0.95
R² = 0.0002
P=1.9E-06